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LETTERS TO THE EDITOR
Drug Interaction
Between
Complementary Herbal
Medicines and
Gefitinib
To the Editor:
Dear Colleagues: We would like to
share with the readers of Journal of Tho-
racic Oncology an interesting case that we
encountered. It serves as a reminder that
we should ask our patients about their use
of complementary medicines. A 36-year-
old woman with no smoking history pre-
sented with progressive dyspnea. Com-
puted tomography (CT) of the chest at
diagnosis showed a main mass in the right
lower lobe with disseminated multiple
nodules and multiple interlobular septal
thickening in both lungs (Fig. 1A). A nee-
dle-aspiration biopsy of the lung nodule
was performed, and its histology was con-
sistent with adenocarcinoma. A diagnosis
of stage IV adenocarcinoma of lung was
made, and she was treated with gefitinib
250 mg per day by mouth as the first-line
chemotherapy. Within 9 weeks of ge-
fitinib treatment, she became progres-
sively symptomatic more short of breath.
A CT scan of chest revealed progression
of her disease (Fig. 1B). She was recom-
mended to discontinue gefitinib because
of progressive disease. However, she de-
sired to continue gefitinib therapy. At that
time, she informed her physician that she
had simultaneously taken multiple com-
plementary herbal medicines including
ginseng, Fomes fomentarius, Inonotus
obliquus, Phellinus linteus, and selenium
along with gefitinib without notification.
Thereafter, she discontinued all comple-
mentary herbal medicines and took only
gefitinib. Her symptoms improved and a
follow-up CT scan of chest obtained after
4 weeks revealed a partial response of her
disease (Fig. 1C). She continued gefitinib
and has been on treatment for 30 weeks
with sustained response of her disease
(Fig. 1D).
The CYP3A4 and CYP3A5 in the
intestines and liver play primary role in
the first-pass metabolism and systemic
clearance of gefitinib.1 Therefore, elevated
CYP3A4/A5 activity through induction
by herbal medicines may result in a de-
crease in plasma concentrations and in
total loss of therapeutic effect of gefitinib.
In this case, the patient took multiple mix-
tures of herbal medicines including gin-
seng, mushrooms, and selenium. Al-
though ginseng is one of the most widely
used herbal medicine, little information is
available on drug interactions. Previously
a randomized trial had demonstrated that
ginseng reduced the anticoagulation ef-
fects of warfarin. Because warfarin is
eliminated extensively through hepatic
CYP enzyme system including CYP1A2,
CYP3A4, and CYP2C9, these data sug-
gest that ginseng may induce the CYP
enzyme system resulting in lower plasma
concentrations of warfarin.2 In addition,
an in vitro study showed that ginseng
increased CYP3A4 mRNA expression
in human hepatocytes.3 These findings
suggest that ginseng may increase the
clearance of gefitinib through CYP3A4
induction, which result in treatment fail-
ure to gefitinib. Besides ginseng, this
patient took mushrooms and selenium.
Although there are no reports on drug
interactions with these complementary
medicines, that we are aware of, the
possibility of drug-interaction with these
medicines and gefitinib should also be
taken in consideration.
To our knowledge, this is the first
report of clinically relevant interaction of
gefitinib with complementary herbal med-
icines. This case demonstrates the possi-
bility of complementary herbal medicines
causing treatment failure in a patient who
was subsequently responsive to gefitinib.
Physicians are encouraged to discuss the
use of complementary medicines with
their patients and to be aware of possible
interaction with gefitinib.
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FIGURE 1. Chest CT before and after gefitinib treatment. Initial CT scan at the
level of right lower lobar bronchus revealed a speculated mass with cavitary
change in the right lower lobe suggesting primary lung cancer. Multiple hema-
togenous metastatic nodules with or without cavitary change were seen in both
lungs (A). On CT scan obtained 9 weeks after gefitinib treatment, the primary
mass in the right lower lobe and pulmonary metastases in both lungs were in-
creased (B). On CT scan obtained 4 weeks after discontinuation of herbal medi-
cines, primary mass and hematogenous metastatic nodules were markedly de-
creased (C). On CT scan obtained a total of 30 weeks after gefitinib treatment,
the primary mass in the right lower lobe was further decreased (D).
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Too Restrictive
Exclusion Criteria in
Advanced Stage Lung
Cancer Therapeutic
Trials: Are We Missing
the Target?
To the Editor:
With 965,000 new cases worldwide
in 2002 in men and 387,000 new cases in
women, lung cancer is the most common
cancer. Because of its poor prognosis,
1.2  106 people died of lung cancer in
that year.1 Though its incidence has
stopped increasing, particularly for men,
in countries where efficient tobacco con-
trol policies have been implemented, its
global incidence is still on the rise.1
This dramatic situation is due to
the high worldwide prevalence of tobacco
smoking and the fact that most diagnoses
are made at advanced stages when only
palliative treatments (chemotherapy ra-
diotherapy) can be prescribed, surgery be-
ing the only curative treatment.1
Obviously, curbing the tobacco
pandemic would be an efficient way to
prevent lung cancer, but worldwide to-
bacco smoking is still on the rise, due
to the tobacco industry’s highly efficient
marketing and promotion efforts. Further-
more, even if tobacco smoking were to
totally vanish, the lung cancer pandemic
would last for a long time since at present,
at least in developed countries, nearly one
in 2 lung cancers are diagnosed in patients
who had already given up smoking.2
An efficient early detection proce-
dure has yet to be described for this
cancer,3 therefore, to improve lung can-
cer prognosis, it is important to try to
improve treatment (chemotherapy  ra-
diotherapy) efficacy. This can only be
done through the development of more
efficient treatments with the enrollment
of patients in clinical trials.
Unfortunately, there are currently
very few patients with advanced stage
lung cancer (less than 5%) enrolled in
clinical trials.4 For example, in our depart-
ment, a prospective study of inclusion/
noninclusion in clinical trials of patients
admitted for stages IIIB and IV nonsmall
cell lung cancer (NSCLC) in 2007 showed
that, among 217 patients admitted for lung
cancer, according to TNM staging, 123
patients with NSCLC (m/f ratio: 96/27;
mean age: 61  12 years; 64 adenocarci-
noma, 32 squamous cell carcinomas, 2
neuroendocrine carcinomas, 2 large cell
carcinomas, 17 undifferentiated carcino-
mas, and 6 without histology) could have
been enrolled in clinical trials open at time
of admission. However, only 12 patients
(10%) were actually included in a trial.
The exclusion criteria were as follows: 
symptomatic brain metastases (n  29),
common comorbidities (Charlson Comor-
bidity Index-CCI- 3) (n  28), WHO
PS 2 and/or life expectancy3 months
(n  23), patient refusal or specified re-
quirements (n  13), technical limitation
(tumor biopsy size too small for further
molecular analysis, n  9), patient trans-
ferred to another institution (n  7), lack
of organization (n  2).
Obviously, such a low percentage
of included patients is not a representa-
tive sample of patients with advanced
NSCLC. Low accrual rates have been
observed in other clinical settings and
several parameters have been suggested
to be responsible: age, ethnicity, insur-
ance status, presence of an oncology
specialist, etc.4,5 In the present study,
these parameters were not involved
since all patients could have been in-
cluded in clinical trials according to
their age, clinical status, TNM staging,
acceptance, etc. Our patients were
mainly not included because of overly
restrictive clinical trial exclusion crite-
ria. As a result, one might question
whether the observations resulting from
therapeutic protocols based on such re-
strictive criteria, inevitably leading to bi-
ased samples of patients, should be ap-
plied to all patients. Thus, it is suggested
that, instead of studying a very exclusive
subset of patients, future protocols should
be targeted toward the main patient pop-
ulation, regardless of clinical status, but
for terminally ill patients.
Christelle Cle´ment-Ducheˆne, MD
Charlotte Carnin, BS
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Zoledronic Acid and
Survival in Patients
with Metastatic Bone
Disease From Lung
Cancer and Elevated
Markers of Osteoclast
Activity: A Novel
Molecular Mechanism
To the Editor:
Dear Sir, I read with great interest
the paper by Hirsh et al.1
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